Lung Cancer

Kristen A. Marrone, MD, discusses research efforts with osimertinib in EGFR-mutated lung cancer, overcoming resistance to the agent, and optimizing sequential molecular testing.

November 19, 2020 - Lorlatinib has been found to significantly prolong progression-free survival, elicit a higher overall and intracranial response, and improve quality of life compared with crizotinib in treatment-naïve patients with advanced ALK-positive non­–small cell lung cancer.

The first biomarker-drive intervention for patients with non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation is now available in clinical practice.

Naiyer A. Rizvi, MD, discusses the rationale to evaluate the investigational glutaminase inhibitor telaglenastat in patients with non–small cell lung cancer who harbor KEAP1 or NRF2 mutations.

Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in ​previously treated patients with non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

November 17, 2020 - The PD-1 inhibitor tislelizumab was found to improve overall survival versus docetaxel in the second- or third-line treatment in patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.

In our exclusive interview, Dr. Raez discusses the reasons for the declines in routine screening and referrals due to the coronavirus disease 2019, anticipated consequences, and some of the ways in which the health care community can combat these newfound challenges.

November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.